Upper Tract Urothelial Carcinoma (UTUC) is a neglected cancer in urology. Due to the relative rarity of UTUC, a great amount of decision-making in UTUC therapeutics comes from evidence based in bladder cancer. However, large number of discoveries have proved that UTUC have different features comparing with bladder cancer. It is shown that with Computed Tomography Urography (CTU), cytology, and ureteroscopy in suspected UTUC, nearly 60% of UTUC are invasive at the time of diagnosis and nearly 25% are metastatic. There is a general lack of high-level evidence on early diagnosis and management of UTUC, such as kidney sparing surgery (KSS), lymph node dissection, neoadjuvant and adjuvant chemotherapy, immune checkpoint inhibition, and systemic therapy for metastatic UTUC.
This Research Topic aims at recent advances on diagnosis and therapy of UTUC, especially about new techniques on early diagnosis of UTUC, KSS and lymph node dissection, neoadjuvant and adjuvant chemotherapy, and immune checkpoint inhibition in UTUC.
• New diagnostic techniques for UTUC, such as confocal laser microscopy, optical coherence tomography
• Radiography techniques and biomarkers for identification of low-risk UTUC VS aggressive UTUC
• Survival data about kidney-sparing surgery (KSS) and lymph node dissection in UTUC
• Neoadjuvant and adjuvant chemotherapy, systemic immunotherapies targeting immune checkpoint inhibition using in UTUC
• Systemic therapy for metastatic UTUC
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Upper Tract Urothelial Carcinoma (UTUC) is a neglected cancer in urology. Due to the relative rarity of UTUC, a great amount of decision-making in UTUC therapeutics comes from evidence based in bladder cancer. However, large number of discoveries have proved that UTUC have different features comparing with bladder cancer. It is shown that with Computed Tomography Urography (CTU), cytology, and ureteroscopy in suspected UTUC, nearly 60% of UTUC are invasive at the time of diagnosis and nearly 25% are metastatic. There is a general lack of high-level evidence on early diagnosis and management of UTUC, such as kidney sparing surgery (KSS), lymph node dissection, neoadjuvant and adjuvant chemotherapy, immune checkpoint inhibition, and systemic therapy for metastatic UTUC.
This Research Topic aims at recent advances on diagnosis and therapy of UTUC, especially about new techniques on early diagnosis of UTUC, KSS and lymph node dissection, neoadjuvant and adjuvant chemotherapy, and immune checkpoint inhibition in UTUC.
• New diagnostic techniques for UTUC, such as confocal laser microscopy, optical coherence tomography
• Radiography techniques and biomarkers for identification of low-risk UTUC VS aggressive UTUC
• Survival data about kidney-sparing surgery (KSS) and lymph node dissection in UTUC
• Neoadjuvant and adjuvant chemotherapy, systemic immunotherapies targeting immune checkpoint inhibition using in UTUC
• Systemic therapy for metastatic UTUC
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
